Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Holdings Trimmed by Strs Ohio

Strs Ohio lowered its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 14.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 127,500 shares of the company’s stock after selling 21,300 shares during the quarter. Strs Ohio’s holdings in Amneal Pharmaceuticals were worth $773,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Phocas Financial Corp. bought a new position in Amneal Pharmaceuticals during the fourth quarter valued at about $4,339,000. Arizona State Retirement System bought a new position in Amneal Pharmaceuticals during the fourth quarter valued at about $183,000. Ritholtz Wealth Management boosted its stake in Amneal Pharmaceuticals by 40.5% during the fourth quarter. Ritholtz Wealth Management now owns 114,225 shares of the company’s stock valued at $693,000 after buying an additional 32,937 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Amneal Pharmaceuticals during the third quarter valued at about $160,000. Finally, Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals during the third quarter valued at about $39,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 12.0 %

Shares of Amneal Pharmaceuticals stock opened at $6.05 on Thursday. The stock has a 50-day moving average price of $5.72 and a 200 day moving average price of $5.17. The company has a market cap of $1.86 billion, a P/E ratio of -19.52 and a beta of 1.33. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals, Inc. has a 1 year low of $1.64 and a 1 year high of $6.46.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.07. The firm had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMRX has been the subject of several analyst reports. The Goldman Sachs Group upped their target price on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a report on Monday, March 4th. Barclays upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, January 29th. Piper Sandler upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.